Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
5 evidence topics · 2 sources
Absorption, dose proportionality, and half-life with once-daily dosing
“BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation with repeated dosing
“BMS-986115 accumulated in plasma following once daily administration in Arms A and B. The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active metabolite BMT-100948
“Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected half-life and rationale for transient target engagement
“As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable. BMS-986115 has a projected human half-life of approximately 15 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Half-life relative to nirogacestat as stated by the company
“Varegacestat is a Gamma Secretase Inhibitor with a” (opens the source at this quote in a new tab)
“Differentiated Pharmacokinetic Profile” (opens the source at this quote in a new tab)
“78% Longer Half-Life than” (opens the source at this quote in a new tab)
“Nirogacestat” (opens the source at this quote in a new tab)
“Sustained Exposure Above” (opens the source at this quote in a new tab)
“1.2 mg Once Daily” (opens the source at this quote in a new tab)
“(3) Immunome data on file” (opens the source at this quote in a new tab)